USPTO Director: Invalidity Judgment by District Court Does Not Foreclose Inter Partes Review

June 5, 2023

Reading Time : 2 min

In a sua sponte review, USPTO Director Kathy Vidal continued her refinement of the PTAB’s “discretionary denial” practice. Specifically, the Director vacated the Board’s decision to deny institution in Volvo Penta of the Americas, LLC v. Brunswick Corp. (IPR2022-01424). In doing so, the Director clarified the PTAB’s statutory authority to institute an IPR and affirmed that the discretionary denial factors set out in Apple Inc. v. Fintiv, Inc. also apply when an invalidated patent is still on appeal.

In Volvo Penta, an inter partes review petition was filed while the same patent was asserted in a co-pending district court lawsuit. After the petition was filed, the district court held that the sole asserted patent claim was invalid under 35 U.S.C. § 101 and dismissed the case.

While the district court’s decision was on appeal, the Board issued a decision denying IPR institution. The Board gave two reasons for its denial. First, the Board concluded that it did not have statutory authority to institute an IPR on a patent claim held invalid by a district court. In support of its reasoning, the Board pointed to the Federal Circuit’s 2020 decision in Uniloc 2017 LLC v. Hulu, LLC, which explained that the Board’s authority to institute under 35 U.S.C. § 311(b) “is confined to the review of existing patent claims.” According to the Board, the invalidity judgment means that the invalidated claim was no longer an “existing” patent claim subject to IPR. The Board further relied on Federal Circuit case law holding that the pendency of an appeal does not affect the binding nature of the district court’s judgment.

Second, the Board side-stepped applying the Fintiv discretionary denial factors, reasoning that they are relevant only when there is a co-pending district court litigation. Because judgment had already been entered in the district court litigation, it was no longer co-pending, and the factors—including the time to trial and the likelihood of a stay—no longer applied. Accordingly, the Board did not consider the Fintiv factors. Instead, the Board determined that instituting an IPR would increase the risk of wasting resources and reaching inconsistent decisions, and denied institution.

Director Vidal vacated the Board’s decision, finding both of the Board’s reasons flawed. According to the Director, the Board applied irrelevant collateral estoppel rules that have no bearing on the PTAB’s statutory authority to institute under § 311(b). The invalidated claim remains in force until any appeals are resolved, and so the Board retains the authority to institute under § 311(b) despite the district court judgment. As the Director explained, this is fully consistent with the Patent Office’s other policies, including that it does not issue a certificate of cancellation in reissues, IPRs, or ex parte reexaminations until after all appeals have been exhausted.

Similarly, the Director held that because the district court’s invalidity decision was “non-final,” the patent was still subject to judicial review and the Fintiv factors still applied. Thus, the case was remanded to the Board with instructions to evaluate the case under Fintiv, and to consider whether to terminate any instituted proceedings if the invalidity determination is upheld on appeal.

Practice Tip: Patent Owners and Petitioners should be aware that a district court’s early-case invalidation of an asserted patent claim does not necessarily bar institution of an IPR so long as the appeal is still pending. Under these circumstances, the parties should consider thoroughly addressing the Fintiv factors before the PTAB.

Volvo Penta of the Americas, LLC v. Brunswick Corp., IPR2022-01424, Paper 12 (P.T.A.B. Feb. 16, 2023).

Share This Insight

Previous Entries

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.